<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://peptidesagora.com/</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/news</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/search</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/about</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/authors</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/forums</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/calculator</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/plotter</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/coa-calculator</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/stability</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/media</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://peptidesagora.com/authors/maya-chen</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/authors/maya-chen.jpg</image:loc>
      <image:title><![CDATA[Maya Chen - Peptides Agora Editorial Correspondent]]></image:title>
      <image:caption><![CDATA[Regulatory Affairs Correspondent covering Regulation & Industry]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/authors/marc-dubois</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/authors/marc-dubois.jpg</image:loc>
      <image:title><![CDATA[Marc Dubois - Peptides Agora Editorial Correspondent]]></image:title>
      <image:caption><![CDATA[Science & Clinical Trials Correspondent covering Research & Clinical Trials]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/authors/lucia-torres</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/authors/lucia-torres.jpg</image:loc>
      <image:title><![CDATA[Lucía Torres - Peptides Agora Editorial Correspondent]]></image:title>
      <image:caption><![CDATA[Culture & Public Health Reporter covering Culture & Wellness]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/authors/amina-yusuf</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/authors/amina-yusuf.jpg</image:loc>
      <image:title><![CDATA[Amina Yusuf - Peptides Agora Editorial Correspondent]]></image:title>
      <image:caption><![CDATA[Public Health Correspondent covering Public Health & Access]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/authors/darius-bennett</loc>
    <lastmod>2026-09-01T05:04:36.161Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/authors/darius-bennett.jpg</image:loc>
      <image:title><![CDATA[Darius Bennett - Peptides Agora Editorial Correspondent]]></image:title>
      <image:caption><![CDATA[Sport & Community Reporter covering Sport & Online Communities]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/amylin-calcitonin-dual-agonists-dacra-energy-homeostasis</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/amylin-calcitonin-dual-agonists-dacra-energy-homeostasis.jpg</image:loc>
      <image:title><![CDATA[DACRA Pharmacology Separates Preclinical Weight Loss From Calcitonin Receptor Risks]]></image:title>
      <image:caption><![CDATA[Dual amylin-calcitonin receptor agonists reduce body weight in preclinical models by engaging AMY1/AMY3 heterodimers, but distinguishing satiation from calcitonin-mediated aversion remains the primary translational challenge for.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/aod-9604-hgh-fragment-177-191-lipolysis-clinical-evidence</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/aod-9604-hgh-fragment-177-191-lipolysis-clinical-evidence.jpg</image:loc>
      <image:title><![CDATA[AOD-9604 Clinical Evidence: Phase 2b Obesity Trial Failure and Regulatory Status]]></image:title>
      <image:caption><![CDATA[Despite robust preclinical lipolysis data in rodents, AOD-9604 did not meet primary weight-loss endpoints in a 534-subject Phase 2b trial. This reference guide distinguishes verified human null results from animal mechanisms and clarifies.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/argireline-acetyl-hexapeptide-8-snare-complex</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/argireline-acetyl-hexapeptide-8-snare-complex.jpg</image:loc>
      <image:title><![CDATA[Acetyl Hexapeptide-8 Safety Ceiling and SNARE Inhibition Mechanics Define Cosmetic Utility]]></image:title>
      <image:caption><![CDATA[The Cosmetic Ingredient Review Expert Panel assessed acetyl hexapeptide-8 as safe at concentrations up to 0.005%. This regulatory determination frames the peptide's market availability distinct from drug approvals, while clinical data.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/bioactive-food-peptides-marine-collagen-skin-barrier</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/bioactive-food-peptides-marine-collagen-skin-barrier.jpg</image:loc>
      <image:title><![CDATA[Oral Bioactive Peptides for Skin Health Require Verified GI Survival and Trials]]></image:title>
      <image:caption><![CDATA[Oral bioactive peptides face sequential barriers including gastric hydrolysis and limited transepithelial transport. This analysis evaluates the validity of simulated digestion kinetics and Caco-2 monolayer assays as predictors of human.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/bpc-157-ibd-crohns-ulcerative-colitis-clinical-data</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/bpc-157-ibd-crohns-ulcerative-colitis-clinical-data.jpg</image:loc>
      <image:title><![CDATA[BPC-157 in IBD: Preclinical Repair Mechanisms Versus Absent Human Efficacy Data]]></image:title>
      <image:caption><![CDATA[Pliva completed a Phase II ulcerative colitis trial for BPC-157 but never published the results, leaving only rodent data to support claims of mucosal repair and fistula healing in humans.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/cgrp-calcitonin-gene-related-peptide-migraine-vascular-tone</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cgrp-calcitonin-gene-related-peptide-migraine-vascular-tone.jpg</image:loc>
      <image:title><![CDATA[CGRP Therapeutics Cross Border Between Clinical Evidence and Peptide Marketing]]></image:title>
      <image:caption><![CDATA[Eight FDA-approved CGRP-targeting therapies now treat migraine by blocking specific receptor complexes, distinguishing verified clinical science from unregulated peptide marketing in bilingual wellness spaces.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/cholecystokinin-cck-satiety-neuro-gastrointestinal-signaling</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cholecystokinin-cck-satiety-neuro-gastrointestinal-signaling.jpg</image:loc>
      <image:title><![CDATA[Cholecystokinin Satiety Signaling Depends on Vagal Afferents, Not Willpower]]></image:title>
      <image:caption><![CDATA[Intravenous CCK-8 infusion reduces meal size in humans by activating vagal CCK-A receptors, a specific peripheral reflex distinct from central anxiety pathways and inaccessible via oral supplementation.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/collagen-peptides-bioavailability-hydrolyzed-vs-topical</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/collagen-peptides-bioavailability-hydrolyzed-vs-topical.jpg</image:loc>
      <image:title><![CDATA[Collagen Peptide Bioavailability Is Proven, but Skin Efficacy Depends on Industry Funding]]></image:title>
      <image:caption><![CDATA[Pharmacokinetic data verifies that specific collagen dipeptides enter human plasma intact. However, independent clinical assessments show no significant dermatological benefit despite confirmed systemic bioavailability, revealing a.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/cortexin-neuropeptide-fractions-traumatic-brain-injury-trials</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cortexin-neuropeptide-fractions-traumatic-brain-injury-trials.jpg</image:loc>
      <image:title><![CDATA[Cortexin Clinical Trials Exist Only for Tissue Extracts, Not Synthetic Analogs]]></image:title>
      <image:caption><![CDATA[Verified cortexin peptide clinical trials for traumatic brain injury exist exclusively for a tissue-derived pharmaceutical approved in Eastern Europe, creating a safety gap when English-language vendors market synthetic analogs using the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/cosmetic-peptides-pharmacology-classification</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cosmetic-peptides-pharmacology-classification.jpg</image:loc>
      <image:title><![CDATA[Cosmetic Peptides Pharmacology: Receptor Mechanisms vs. Clinical Evidence Limits]]></image:title>
      <image:caption><![CDATA[Cosmetic peptides function through receptor-mediated signaling or neuromodulation, yet clinical evidence remains constrained by molecular weight barriers and study design limitations. This regulatory brief examines the pharmacological gap.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/cyclic-antimicrobial-peptides-polymyxin-daptomycin-pharmacology</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cyclic-antimicrobial-peptides-polymyxin-daptomycin-pharmacology.jpg</image:loc>
      <image:title><![CDATA[Cyclic Antimicrobial Peptide Pharmacology: LPS Binding Versus Renal Uptake]]></image:title>
      <image:caption><![CDATA[Clinical utility for cyclic antimicrobial peptides depends on the quantifiable divergence between bacterial membrane binding and host renal accumulation. Pharmacokinetic dossiers and cellular assays reveal the boundaries of this.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/decapeptide-12-lumixyl-tyrosinase-safety-vs-hydroquinone</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/decapeptide-12-lumixyl-tyrosinase-safety-vs-hydroquinone.jpg</image:loc>
      <image:title><![CDATA[Decapeptide-12 Kinetics Define Regulatory Safety Margin Over Hydroquinone]]></image:title>
      <image:caption><![CDATA[Stanford researchers designed Decapeptide-12 to competitively bind human tyrosinase without inducing melanocyte cytotoxicity. Published Lineweaver-Burk analyses and comparative assays demonstrate this kinetic selectivity distinguishes the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/dipeptide-2-eye-puffiness-capillary-permeability</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/dipeptide-2-eye-puffiness-capillary-permeability.jpg</image:loc>
      <image:title><![CDATA[Dipeptide-2 Eye Contour Claims Rest on Proprietary Morphometry, Not Independent Assays]]></image:title>
      <image:caption><![CDATA[Dipeptide-2 is marketed for periorbital puffiness based on supplier-generated 3D morphometric studies of multi-ingredient complexes. Public regulatory filings and independent literature lack specific lymphatic circulation biomarker assays.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/elastin-derived-peptides-vgvapg-fibroblast-senescence</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/elastin-derived-peptides-vgvapg-fibroblast-senescence.jpg</image:loc>
      <image:title><![CDATA[VGVAPG Signaling Mechanics: ERC Binding Kinetics and Fibroblast Chemotaxis]]></image:title>
      <image:caption><![CDATA[VGVAPG binds the elastin receptor complex at nanomolar concentrations to trigger fibroblast chemotaxis and MMP-2 expression. Structural characterization defines the specific GxxPG conformation required for this bioactivity, distinguishing.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/endorphins-vs-enkephalins-endogenous-opioid-peptide-biochemistry</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/endorphins-vs-enkephalins-endogenous-opioid-peptide-biochemistry.jpg</image:loc>
      <image:title><![CDATA[Endorphins vs. Enkephalins: Biochemistry and Pain Modulation Explained]]></image:title>
      <image:caption><![CDATA[Endorphins and enkephalins are distinct endogenous opioids defined by precursor proteins and receptor selectivity. This guide details enzymatic processing, binding kinetics, and corrects misconceptions about exercise-induced euphoria using.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/galanin-peptide-receptor-signaling-mood-memory-neuroprotection</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/galanin-peptide-receptor-signaling-mood-memory-neuroprotection.jpg</image:loc>
      <image:title><![CDATA[Galanin Claims Outpace Clinical Evidence as Receptor Complexity Stalls Drug Development]]></image:title>
      <image:caption><![CDATA[Online wellness communities market galanin peptides for memory and mood support, yet no approved therapeutics target these receptors and human efficacy data remains absent despite decades of research.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/glow-stack-aesthetic-medicine-ghk-bpc-tb500</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/glow-stack-aesthetic-medicine-ghk-bpc-tb500.jpg</image:loc>
      <image:title><![CDATA[Glow Stack Peptides Lack Clinical Synergy Data Despite Regenerative Marketing Claims]]></image:title>
      <image:caption><![CDATA[No published clinical trial has tested the fixed combination of GHK-Cu, BPC-157, and TB-500 as a unified formulation. This guide maps verified individual mechanisms against regulatory status and compounding constraints for aesthetic.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/histatins-oral-wound-healing-salivary-antifungal-peptides</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/histatins-oral-wound-healing-salivary-antifungal-peptides.jpg</image:loc>
      <image:title><![CDATA[Histatin Mechanisms in Oral Wound Closure and Candida Defense]]></image:title>
      <image:caption><![CDATA[Cell culture models demonstrate that histatins drive oral mucosal repair through integrin-mediated migration and non-lytic antifungal activity, yet no human trials have validated synthetic formulations for clinical wound treatment.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/human-beta-defensins-antimicrobial-mucosal-barrier</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/human-beta-defensins-antimicrobial-mucosal-barrier.jpg</image:loc>
      <image:title><![CDATA[Human Beta-Defensin Immunology: Structural Stability, MIC Data, and Barrier Limits]]></image:title>
      <image:caption><![CDATA[In vitro NMR data confirms hBD-3 dimer stability, yet human nasal epithelial cell models show hBD-2 only partially restores barrier integrity after MRSA infection, highlighting a gap between structural potency and clinical repair.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/immunosenescence-thymic-involution-peptide-therapeutics</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/immunosenescence-thymic-involution-peptide-therapeutics.jpg</image:loc>
      <image:title><![CDATA[Thymic Peptides in Immunosenescence: Distinguishing Regeneration from Expansion]]></image:title>
      <image:caption><![CDATA[Peptide interventions for immunosenescence operate through distinct biological pathways. Evidence from thymic epithelial cell models and flow cytometry datasets separates agents targeting thymopoiesis from those expanding peripheral memory.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/klow-stack-chronic-inflammation-kpv-ll37-bpc157</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/klow-stack-chronic-inflammation-kpv-ll37-bpc157.jpg</image:loc>
      <image:title><![CDATA[KLOW Blend Pharmacology: Component Mechanisms vs. Absent Combination Safety Data]]></image:title>
      <image:caption><![CDATA[KLOW combines four peptides with distinct preclinical mechanisms but no verified combination data. This review analyzes the theoretical NF-κB and angiogenesis overlap of KPV, BPC-157, TB-500, and GHK-Cu against the complete lack of human.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/kpv-peptide-alpha-msh-nfkb-inhibition-gut-barrier</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/kpv-peptide-alpha-msh-nfkb-inhibition-gut-barrier.jpg</image:loc>
      <image:title><![CDATA[KPV Mechanism Relies on PepT1 Transport and NF-κB Inhibition in Murine Colitis Models]]></image:title>
      <image:caption><![CDATA[Nanomolar KPV concentrations inhibit NF-κB activation in Caco-2 cells and murine DSS-colitis models through PepT1 transport, yet this mechanism lacks validation in completed human clinical trials.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/matrixyl-palmitoyl-pentapeptide-collagen-stimulation</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/matrixyl-palmitoyl-pentapeptide-collagen-stimulation.jpg</image:loc>
      <image:title><![CDATA[Matrixyl Collagen Claims: Separating In Vitro Assays From Topical Evidence]]></image:title>
      <image:caption><![CDATA[Sederma’s proprietary fibroblast assays report 117% collagen synthesis increases, yet human clinical endpoints for Matrixyl depend on surface imaging without biopsy verification. This distinction defines current regulatory and formulation.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/neuropeptide-y-npy-stress-resilience-anxiolysis-autonomic</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/neuropeptide-y-npy-stress-resilience-anxiolysis-autonomic.jpg</image:loc>
      <image:title><![CDATA[Neuropeptide Y and Stress Resilience: Separating Clinical Evidence from Wellness Claims]]></image:title>
      <image:caption><![CDATA[While wellness communities promote Neuropeptide Y as a direct cortisol reducer, clinical literature defines it as a complex resilience mediator. This guide examines verified HPA axis assays, receptor binding kinetics, and intranasal PTSD.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/neuropeptides-cns-signaling-dsip-oxytocin-neurotrophic</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/neuropeptides-cns-signaling-dsip-oxytocin-neurotrophic.jpg</image:loc>
      <image:title><![CDATA[Neuropeptide CNS Therapeutics: Blood-Brain Barrier Kinetics and Clinical Biomarkers]]></image:title>
      <image:caption><![CDATA[Neuropeptides regulate diverse CNS functions, but therapeutic efficacy depends on verified blood-brain barrier transport and clinical biomarker readouts rather than marketing claims. This pillar examines the pharmacokinetic evidence.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/nonapeptide-1-melanogenesis-hyperpigmentation-skin-brightening</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/nonapeptide-1-melanogenesis-hyperpigmentation-skin-brightening.jpg</image:loc>
      <image:title><![CDATA[Nonapeptide-1 Binds MC1R at 40 nM, but Human Efficacy Data Remains Sparse]]></image:title>
      <image:caption><![CDATA[Nonapeptide-1 functions as a competitive MC1R antagonist with a binding affinity of 40 nM, blocking alpha-MSH from initiating melanogenesis. While B16 melanoma cell models demonstrate dose-dependent melanin reduction without cytotoxicity.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/nootropic-peptide-stacking-pharmacokinetic-interference-risks</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/nootropic-peptide-stacking-pharmacokinetic-interference-risks.jpg</image:loc>
      <image:title><![CDATA[Nootropic Peptide Stacking Safety Depends on Washout Kinetics, Not Vendor Protocols]]></image:title>
      <image:caption><![CDATA[Pharmacological safety standards define a mandatory five-half-life washout period to ensure compound clearance before introducing new peptides, preventing cumulative receptor downregulation that vendor stacking guides frequently omit.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/oligopeptide-68-tgf-beta-melasma-skin-tone</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oligopeptide-68-tgf-beta-melasma-skin-tone.jpg</image:loc>
      <image:title><![CDATA[Oligopeptide-68 Suppresses MITF Transcription to Treat Melasma Safely]]></image:title>
      <image:caption><![CDATA[Oligopeptide-68 reduces melasma by antagonizing TGF-β receptors to suppress MITF transcription, lowering tyrosinase, TRP-1, and TRP-2 expression. Clinical trials demonstrate pigment reduction comparable to hydroquinone without cytotoxicity.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/orexin-hypocretin-peptides-sleep-arousal-narcolepsy-dora</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/orexin-hypocretin-peptides-sleep-arousal-narcolepsy-dora.jpg</image:loc>
      <image:title><![CDATA[Orexin Signaling Diverges Between Insomnia Antagonists and Narcolepsy Agonists]]></image:title>
      <image:caption><![CDATA[Orexin neurons stabilize wakefulness through distinct receptor pathways. This analysis examines verified projection mapping, binding kinetics, and trial data to differentiate dual orexin receptor antagonists for insomnia from selective.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/oxytocin-intranasal-pharmacology-social-neuroendocrine-stress</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oxytocin-intranasal-pharmacology-social-neuroendocrine-stress.jpg</image:loc>
      <image:title><![CDATA[Intranasal Oxytocin Pharmacology: Neural Shifts Without Behavioral Gains]]></image:title>
      <image:caption><![CDATA[Intranasal oxytocin reliably alters threat-processing circuitry in imaging studies 45 to 70 minutes post-dose, but systematic reviews of chronic administration in autism spectrum disorder find no corresponding improvement in social.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/palmitoyl-tetrapeptide-7-photoaging-interleukin-suppression</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/palmitoyl-tetrapeptide-7-photoaging-interleukin-suppression.jpg</image:loc>
      <image:title><![CDATA[Palmitoyl Tetrapeptide-7: IL-6 Suppression Data Defines Cosmetic Boundaries]]></image:title>
      <image:caption><![CDATA[In vitro assays show palmitoyl tetrapeptide-7 reduces UV-induced IL-6 secretion in keratinocytes by up to 86%, yet this mechanistic data remains distinct from approved drug indications. This guide separates verified cell-model findings.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-lip-care-formulations-palmitoyl-tripeptide-1</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-lip-care-formulations-palmitoyl-tripeptide-1.jpg</image:loc>
      <image:title><![CDATA[Palmitoyl Tripeptide-1 Lip Claims Face Scrutiny Amid Clinical Gaps]]></image:title>
      <image:caption><![CDATA[Manufacturer dossiers for palmitoyl tripeptide-1 demonstrate collagen and glycosaminoglycan upregulation in fibroblast cultures, yet independent randomized controlled trials confirming measurable lip volume increase via topical application.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-vaccines-neoantigens-epitope-cancer-immunotherapy</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-vaccines-neoantigens-epitope-cancer-immunotherapy.jpg</image:loc>
      <image:title><![CDATA[Neoantigen Peptide Vaccines: Prediction Accuracy Versus Clinical T-Cell Expansion]]></image:title>
      <image:caption><![CDATA[Computational algorithms predict HLA binding for neoantigen peptide vaccines, yet only 10–20% of selected epitopes induce measurable T-cell responses in patients. This reference examines the discordance between in silico prediction metrics.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/pinealon-edr-peptide-neuronal-gene-expression-circadian</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/pinealon-edr-peptide-neuronal-gene-expression-circadian.jpg</image:loc>
      <image:title><![CDATA[Pinealon’s DNA-Binding Claim: Separating Khavinson Institute Models from Clinical Proof]]></image:title>
      <image:caption><![CDATA[English and Spanish wellness vendors market Pinealon as a gene-regulating nootropic, yet the sole supporting research originates from the Khavinson Institute. This report traces the EDR tripeptide from bovine cortex isolation to unverified.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/pt-141-bremelanotide-vyleesi-mc4r-sexual-desire-clinical-pharmacology</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/pt-141-bremelanotide-vyleesi-mc4r-sexual-desire-clinical-pharmacology.jpg</image:loc>
      <image:title><![CDATA[Bremelanotide Clinical Pharmacology: MC4R Agonism and RECONNECT Trial Outcomes in HSDD]]></image:title>
      <image:caption><![CDATA[FDA approval for bremelanotide in premenopausal HSDD rests on Phase 3 RECONNECT trials showing modest effect sizes and mechanism-linked nausea, while European regulators have not authorized the peptide for clinical use.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/retatrutide-triple-agonist-triumph-phase-3-energy-expenditure</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/retatrutide-triple-agonist-triumph-phase-3-energy-expenditure.jpg</image:loc>
      <image:title><![CDATA[Retatrutide Triple Agonism: TRIUMPH Phase 3 Architecture and Energy Expenditure Data]]></image:title>
      <image:caption><![CDATA[Retatrutide achieved 30.3% mean weight loss at 104 weeks in the Phase 3 TRIUMPH-1 trial. This analysis examines the triple-agonist protocol architecture and pending regulatory submissions.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/semax-vs-selank-pharmacological-comparison-nootropic-axis</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/semax-vs-selank-pharmacological-comparison-nootropic-axis.jpg</image:loc>
      <image:title><![CDATA[Semax and Selank: Translating Russian Clinical Data for English-Speaking Wellness Markets]]></image:title>
      <image:caption><![CDATA[Wellness communities frequently stack Semax and Selank as complementary cognitive tools, yet Russian regulatory records define them as distinct agents for stroke recovery and anxiety disorders respectively. This divergence persists despite.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/targeted-lipolytic-peptides-aod-9604-pt-141-thermodynamics</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/targeted-lipolytic-peptides-aod-9604-pt-141-thermodynamics.jpg</image:loc>
      <image:title><![CDATA[AOD-9604 and PT-141: Divergent Lipolytic Mechanisms in Human Adipose Tissue]]></image:title>
      <image:caption><![CDATA[Heffernan et al. established AOD-9604 lipolysis via beta-3 adrenergic receptors in mice, yet human subcutaneous adipocytes show minimal functional response to this pathway while PT-141 modulates energy balance centrally.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/tirzepatide-standalone-gip-glp1-dual-agonism-clinical-pharmacology</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tirzepatide-standalone-gip-glp1-dual-agonism-clinical-pharmacology.jpg</image:loc>
      <image:title><![CDATA[Tirzepatide Dual Agonism: SURMOUNT Efficacy Data and Pharmacological Mechanisms]]></image:title>
      <image:caption><![CDATA[Tirzepatide demonstrates dose-dependent weight reduction up to 22.5% in SURMOUNT-1 through 4 Phase 3 trials via dual GIP/GLP-1 receptor agonism. This reference guide examines the pharmacological mechanisms, clinical endpoints, and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/topical-vs-injectable-copper-peptides-ghk-cu</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/topical-vs-injectable-copper-peptides-ghk-cu.jpg</image:loc>
      <image:title><![CDATA[Topical Versus Injectable GHK-Cu: Franz Cell Diffusion Data and Regulatory Evidence Gaps]]></image:title>
      <image:caption><![CDATA[In vitro Franz cell diffusion models demonstrate that aqueous GHK-Cu penetrates the stratum corneum poorly compared to liposomal formulations, yet no head-to-head human trials validate injectable superiority for skin endpoints.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/tripeptide-29-collagen-fibrillogenesis-stretch-marks</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tripeptide-29-collagen-fibrillogenesis-stretch-marks.jpg</image:loc>
      <image:title><![CDATA[Tripeptide-29 Mechanisms: In Vitro Collagen Synthesis and MMP Regulation Data]]></image:title>
      <image:caption><![CDATA[Manufacturer in vitro studies show Tripeptide-29 boosts type I collagen synthesis by 400% in fibroblasts, but the absence of human trials restricts U.S. marketing to cosmetic structure-function claims.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/tuftsin-phagocytosis-macrophage-activation-spleen</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tuftsin-phagocytosis-macrophage-activation-spleen.jpg</image:loc>
      <image:title><![CDATA[Tuftsin Macrophage Activation: Neuropilin-1 Kinetics vs Clinical Efficacy]]></image:title>
      <image:caption><![CDATA[Tuftsin stimulates macrophage phagocytosis via specific neuropilin-1 binding with a dissociation constant of 5.3 × 10⁻⁸ M. In vitro assays confirm enhanced phagocytic indices, while structural analogs like selank address native peptide.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/vip-aviptadil-vasoactive-intestinal-peptide-ards-pulmonary</loc>
    <lastmod>2026-09-01T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/vip-aviptadil-vasoactive-intestinal-peptide-ards-pulmonary.jpg</image:loc>
      <image:title><![CDATA[Aviptadil in ARDS: Divergent Trial Endpoints and Alveolar Type II Signaling]]></image:title>
      <image:caption><![CDATA[Phase 3 randomized controlled trials of aviptadil in critical respiratory failure failed to meet primary endpoints for survival free of respiratory failure at 60 days. Despite this, post-hoc analyses and mechanistic data on VPAC1-mediated.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/503a-vs-503b-compounding-pharmacy-regulations</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/503a-vs-503b-compounding-pharmacy-regulations.jpg</image:loc>
      <image:title><![CDATA[503A vs 503B Peptide Compounding: Statutory Limits and Enforcement Realities]]></image:title>
      <image:caption><![CDATA[The Drug Quality and Security Act established two separate regulatory frameworks for compounding peptides. Section 503A requires patient-specific prescriptions and state oversight, while Section 503B mandates cGMP compliance and FDA.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/bpc-157-stable-arginate-vs-acetate</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/bpc-157-stable-arginate-vs-acetate.jpg</image:loc>
      <image:title><![CDATA[BPC-157 Pharmacology: Salt Stability, VEGFR2 Signaling, and the Clinical Evidence Gap]]></image:title>
      <image:caption><![CDATA[BPC-157 is a synthetic pentadecapeptide with a robust preclinical record but a critically undercharacterized human pharmacokinetic profile. This report examines the chemical differences between arginate and acetate salts, the VEGFR2-Akt-eNOS signaling pathway, and the specific limitations of animal-to-human translation.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/bryan-johnson-dog-wolverine-stack-veterinary</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/bryan-johnson-dog-wolverine-stack-veterinary.jpg</image:loc>
      <image:title><![CDATA[Bryan Johnson's Dog Post Puts 'Wolverine Stack' Peptides Under Veterinary Scrutiny]]></image:title>
      <image:caption><![CDATA[Bryan Johnson's September 12 X post referencing the BPC-157 and TB-500 'Wolverine Stack' for his dog arrived six weeks after an FDA advisory panel recommended the peptides for human compounding, a designation that does not extend to.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/cagrilintide-amylin-agonism-mechanisms</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cagrilintide-amylin-agonism-mechanisms.jpg</image:loc>
      <image:title><![CDATA[Cagrilintide Pharmacology Defined by Dual Receptor Agonism and REDEFINE Trial Efficacy]]></image:title>
      <image:caption><![CDATA[Novo Nordisk’s Phase 3 REDEFINE 1 trial established that cagrilintide functions as a dual amylin and calcitonin receptor agonist, producing 20.4% mean weight loss when combined with semaglutide. This efficacy relies on specific activation.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/cjc-1295-dac-vs-sermorelin-mod-grf</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cjc-1295-dac-vs-sermorelin-mod-grf.jpg</image:loc>
      <image:title><![CDATA[CJC-1295 vs Sermorelin: Half-Life, Albumin Binding, and the Evidence Gap]]></image:title>
      <image:caption><![CDATA[CJC-1295 with DAC extends growth hormone exposure to eight days via albumin binding, while sermorelin clears in minutes. This structural divergence creates distinct safety monitoring needs and access barriers that clinical guidelines have.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/custom-peptide-synthesis-purification</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/custom-peptide-synthesis-purification.jpg</image:loc>
      <image:title><![CDATA[FDA Impurity Guidance Forces Re-evaluation of Solid-Phase Peptide Synthesis Protocols]]></image:title>
      <image:caption><![CDATA[FDA expectations for controlling deletion sequences and process-related impurities in synthetic peptides are reshaping solid-phase peptide synthesis protocols, forcing manufacturers to balance coupling efficiency against regulatory.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/epitalon-telomerase-pineal-peptide-evidence</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/epitalon-telomerase-pineal-peptide-evidence.jpg</image:loc>
      <image:title><![CDATA[Epitalon Telomerase Claims Rest on Single-Lab In Vitro Data and Unreplicated Cohorts]]></image:title>
      <image:caption><![CDATA[Claims that Epitalon extends human lifespan rely primarily on a 2003 in vitro study showing telomerase induction in fetal fibroblasts and open-label Russian cohort observations. No independent, controlled human trials confirm these.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-backs-6-peptides-compounding</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-backs-6-peptides-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Panel Overrides Staff Scientists to Back Six Peptides for 503A Compounding]]></image:title>
      <image:caption><![CDATA[A reconstituted advisory panel voted against FDA staff recommendations on six of seven peptides, opening a rulemaking path for compounds with no completed Phase 3 trials.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-peptide-reversal-glp-1-compounding-divide</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-peptide-reversal-glp-1-compounding-divide.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Backs 6 Compounded Peptides as Agency Moves to Exclude GLP-1s]]></image:title>
      <image:caption><![CDATA[In a regulatory divergence with few precedents, the FDA's Pharmacy Compounding Advisory Committee backed BPC-157 and five other peptides for compounding eligibility despite internal scientific dissent, even as the agency moved to.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-split-verdict-peptides-glp1-compounding</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-split-verdict-peptides-glp1-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Splits Peptide Path: Panel Backs BPC-157 as GLP-1 Compounding Faces Ban]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee narrowly backed BPC-157, TB-500, and four other peptides for small-scale compounding, even as the agency proposed a permanent exclusion of semaglutide and tirzepatide from large-scale.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/ghk-cu-copper-peptide-collagen-tissue-remodeling</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ghk-cu-copper-peptide-collagen-tissue-remodeling.jpg</image:loc>
      <image:title><![CDATA[GHK-Cu Evidence Base: Fibroblast Assays, Gene Profiling, and Clinical Limits]]></image:title>
      <image:caption><![CDATA[GHK-Cu stimulates collagen synthesis in fibroblast cultures at nanomolar concentrations and modulates thousands of genes in genomic assays, yet human clinical trials remain small and fragmented. This review separates established in vitro.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/ghrh-vs-ghrp-growth-hormone-pathways</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ghrh-vs-ghrp-growth-hormone-pathways.jpg</image:loc>
      <image:title><![CDATA[GHRH and GHRP Secretagogues Operate Through Distinct Pituitary Receptor Pathways]]></image:title>
      <image:caption><![CDATA[GHRH analogs activate Gαs-cAMP signaling on pituitary somatotrophs to support GH synthesis, while GHRPs engage GHSR-1a via Gαq-calcium pathways to trigger release and suppress somatostatin. These distinct mechanisms create synergistic.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/glp-1-gip-glucagon-multi-agonist-comparison</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/glp-1-gip-glucagon-multi-agonist-comparison.jpg</image:loc>
      <image:title><![CDATA[FDA MASH Approval Sets Efficacy Bar for Multi-Receptor Incretin Peptides]]></image:title>
      <image:caption><![CDATA[The FDA’s 2025 accelerated approval of semaglutide for metabolic dysfunction-associated steatohepatitis redefined the regulatory standard for multi-receptor incretin peptides, forcing developers of tirzepatide and retatrutide to validate.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/grey-market-peptides-contamination-risks</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/grey-market-peptides-contamination-risks.jpg</image:loc>
      <image:title><![CDATA[FDA Warning Letters and Lab Data Define Grey Market Peptide Contamination Risks]]></image:title>
      <image:caption><![CDATA[The FDA issued warning letters to Gram Peptides and Wholesale Peptide in 2026 as independent testing confirmed bacterial endotoxins, heavy metals, and incorrect active ingredients in 30% of grey market samples.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/how-to-read-peptide-coa-hplc-testing</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/how-to-read-peptide-coa-hplc-testing.jpg</image:loc>
      <image:title><![CDATA[Reading Peptide COAs: HPLC Purity, Net Content, and Documentation Standards]]></image:title>
      <image:caption><![CDATA[A peptide Certificate of Analysis documents batch-specific analytical results but does not establish clinical safety or regulatory approval. Interpreting these records requires distinguishing chromatographic purity from net peptide content.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/ipamorelin-vs-ghrp-secretagogues</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ipamorelin-vs-ghrp-secretagogues.jpg</image:loc>
      <image:title><![CDATA[Ipamorelin Selectivity Defined by Absence of Cortisol and Prolactin Response]]></image:title>
      <image:caption><![CDATA[Raun and Hansen established ipamorelin as the first selective growth hormone secretagogue in 1998, demonstrating GH release without concurrent ACTH, cortisol, or prolactin elevation at doses 200 times the effective threshold. This.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/lilly-retatrutide-black-market-lawsuits</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/lilly-retatrutide-black-market-lawsuits.jpg</image:loc>
      <image:title><![CDATA[Lilly's Six Lawsuits Target Black-Market Sellers of Unapproved Retatrutide]]></image:title>
      <image:caption><![CDATA[By suing compounding pharmacies, medical spas, and online peptide sellers before retatrutide reaches a pharmacy shelf, Eli Lilly is asking federal courts to enforce a market boundary that does not yet exist in law.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/mots-c-mitochondrial-derived-peptide-ampk</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/mots-c-mitochondrial-derived-peptide-ampk.jpg</image:loc>
      <image:title><![CDATA[MOTS-c Mechanism and Evidence Gaps: From Mitochondrial ORF to Preclinical AMPK Activation]]></image:title>
      <image:caption><![CDATA[MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene that regulates metabolic homeostasis via AMPK activation in mice. While Lee et al. (2015) demonstrated improved insulin sensitivity and exercise capacity in.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/mounjaro-cardiovascular-indication-approval</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/mounjaro-cardiovascular-indication-approval.jpg</image:loc>
      <image:title><![CDATA[FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes]]></image:title>
      <image:caption><![CDATA[Eli Lilly's dual GIP/GLP-1 agonist Mounjaro received FDA authorization to reduce cardiovascular death, heart attack, and stroke risk in adults with type 2 diabetes, matching Novo Nordisk's earlier Ozempic indication through a different.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/nad-precursors-vs-mitochondrial-peptides</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/nad-precursors-vs-mitochondrial-peptides.jpg</image:loc>
      <image:title><![CDATA[NAD+ Precursors vs Mitochondrial Peptides: Regulatory and Biochemical Distinctions]]></image:title>
      <image:caption><![CDATA[Published records define NAD+ as a consumable substrate for sirtuins and PARPs, while peptides like MOTS-c and SS-31 act as upstream regulators of AMPK and cristae structure. This distinction determines clinical evidence standards and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/oral-glp1-phase-3-12-weight-loss</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oral-glp1-phase-3-12-weight-loss.jpg</image:loc>
      <image:title><![CDATA[Ascletis Doses First Patient in 4,600-Person Oral GLP-1 Phase 3 Program]]></image:title>
      <image:caption><![CDATA[The first participant received ASC30 in Ascletis' global Phase 3 program on August 30, 2026. The AURORA trials will enroll approximately 4,600 adults across the U.S. and Europe, though no interim efficacy data has been reported. The.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/oral-peptide-delivery-bioavailability</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oral-peptide-delivery-bioavailability.jpg</image:loc>
      <image:title><![CDATA[Oral Peptide Bioavailability Is Defined by 1% Absorption and Strict Dosing Protocols]]></image:title>
      <image:caption><![CDATA[Regulatory approval of oral semaglutide demonstrated that systemic peptide delivery does not require high bioavailability. Instead, clinical efficacy depends on co-formulating permeation enhancers like SNAC with strict administration.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-immunogenicity-neutralizing-antibodies</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-immunogenicity-neutralizing-antibodies.jpg</image:loc>
      <image:title><![CDATA[FDA Immunogenicity Standards Persist for Peptides Despite Compounding Access Votes]]></image:title>
      <image:caption><![CDATA[The FDA requires risk-based immunogenicity assessment for all therapeutic peptides, including tiered anti-drug antibody testing and impurity characterization. These regulatory standards define safety expectations for approved products and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-reconstitution-storage-manual</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-reconstitution-storage-manual.jpg</image:loc>
      <image:title><![CDATA[Peptide Reconstitution Protocols Depend on Diluent Chemistry and Vial Physics]]></image:title>
      <image:caption><![CDATA[Peptide reconstitution protocols define the chemical and physical parameters necessary to convert lyophilized powders into stable solutions. This reference details diluent selection matrices, vial vacuum dynamics, concentration formulas.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-therapy-fda-approved-vs-experimental</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-therapy-fda-approved-vs-experimental.jpg</image:loc>
      <image:title><![CDATA[FDA-Approved Peptides Versus Compounding Eligibility: A Regulatory Reference]]></image:title>
      <image:caption><![CDATA[An FDA advisory committee voted in July 2026 to recommend easing restrictions on six peptides despite agency objections. This recommendation addresses compounding eligibility under Section 503A and does not constitute drug approval or.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptides-for-tendon-ligament-healing</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptides-for-tendon-ligament-healing.jpg</image:loc>
      <image:title><![CDATA[Orthopedic Peptide Evidence: Preclinical Tendon Repair vs. Human Regulatory Status]]></image:title>
      <image:caption><![CDATA[Current orthopedic literature records consistent tendon repair in rodent models using BPC-157 and TB-500, yet human clinical data remains restricted to safety pilots. This analysis maps the specific evidentiary boundary where preclinical.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/reconstitution-mass-calculator-guide</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/reconstitution-mass-calculator-guide.jpg</image:loc>
      <image:title><![CDATA[FDA Guidance Forces Peptide Calculator Standards to Address U-100 Measurement Liability]]></image:title>
      <image:caption><![CDATA[The FDA's clinical pharmacology guidance for peptide drug products defines characterization standards that transform reconstitution math from a laboratory preference into a regulatory compliance requirement. U-100 syringe units measure.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/research-peptides-quality-verification</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/research-peptides-quality-verification.jpg</image:loc>
      <image:title><![CDATA[Research Peptide Quality Is Defined by Batch Documentation, Not Purity Claims]]></image:title>
      <image:caption><![CDATA[Verifying research peptide quality requires auditing batch-specific Certificates of Analysis for dual HPLC and mass spectrometry data, confirming third-party testing accreditation, and validating supply chain traceability against.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/research-use-only-ruo-legal-taxonomy</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/research-use-only-ruo-legal-taxonomy.jpg</image:loc>
      <image:title><![CDATA[Research Use Only Peptides Are Legal Only When Intent Is Restricted to Laboratory Work]]></image:title>
      <image:caption><![CDATA[Research Use Only peptides are legal in the United States only when sold and used strictly for laboratory investigation. FDA regulations base this status on documented intent rather than product labeling alone.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/selank-anxiolytic-gaba-immune-modulation</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/selank-anxiolytic-gaba-immune-modulation.jpg</image:loc>
      <image:title><![CDATA[Selank Pharmacology: Russian Clinical Approval Versus U.S. Regulatory Status]]></image:title>
      <image:caption><![CDATA[The Russian Ministry of Health approved Selank for generalized anxiety disorder based on domestic trials showing efficacy comparable to medazepam. U.S. regulators classify the same heptapeptide as an unapproved new drug, creating a supply.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/semax-bdnf-neuroprotection-mechanisms</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/semax-bdnf-neuroprotection-mechanisms.jpg</image:loc>
      <image:title><![CDATA[Semax Pharmacology: BDNF Upregulation Evidence Versus Regulatory Divergence]]></image:title>
      <image:caption><![CDATA[Semax increases BDNF mRNA and protein in rodent models and shows functional improvement in Russian stroke registries, yet lacks FDA or EMA approval. This review examines the transatlantic evidence gap between molecular mechanism and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/ss-31-elamipretide-mitochondrial-cardiolipin</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ss-31-elamipretide-mitochondrial-cardiolipin.jpg</image:loc>
      <image:title><![CDATA[FDA Accelerated Approval Defines Elamipretide SS-31 Cardiolipin Pharmacology]]></image:title>
      <image:caption><![CDATA[The FDA’s September 2025 accelerated approval of elamipretide for Barth syndrome establishes cardiolipin stabilization as a validated regulatory mechanism, anchoring SS-31 pharmacology to the inner mitochondrial membrane.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/survodutide-mazdutide-glp1-glucagon-agonists</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/survodutide-mazdutide-glp1-glucagon-agonists.jpg</image:loc>
      <image:title><![CDATA[FDA Approval of Semaglutide for MASH Establishes Benchmark for Dual Agonist Development]]></image:title>
      <image:caption><![CDATA[The FDA approved semaglutide for adult MASH in August 2025, establishing the first GLP-1-based therapy for this indication and defining the histological benchmarks for subsequent dual agonist filings.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/tb-500-thymosin-beta-4-actin-regulation</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tb-500-thymosin-beta-4-actin-regulation.jpg</image:loc>
      <image:title><![CDATA[TB-500 Fragment Versus Thymosin Beta-4: Actin Mechanisms and Evidence Gaps]]></image:title>
      <image:caption><![CDATA[TB-500 is a synthetic seven-amino-acid fragment distinct from the 43-amino-acid thymosin beta-4 protein used in human trials. While both sequester G-actin to regulate cell migration, clinical efficacy data exists only for the full-length.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/tesamorelin-visceral-adiposity-lipodystrophy</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tesamorelin-visceral-adiposity-lipodystrophy.jpg</image:loc>
      <image:title><![CDATA[Tesamorelin Clinical Evidence: FDA Lipodystrophy Approval vs. Liver Data]]></image:title>
      <image:caption><![CDATA[The FDA approved tesamorelin solely for reducing excess abdominal fat in HIV-associated lipodystrophy based on Phase 3 CT data. Hepatic steatosis improvements observed in separate trials remain outside the labeled indication.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/tiktok-teens-unregulated-peptides-danger</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tiktok-teens-unregulated-peptides-danger.jpg</image:loc>
      <image:title><![CDATA[TikTok Looksmaxxing Is Pushing Teens to Inject Unregulated Peptides]]></image:title>
      <image:caption><![CDATA[Teens are self-injecting peptides sold online as 'for research use only,' following tutorials on TikTok. FDA reviewers found the human safety data barely exists, and no agency has closed the regulatory gap that lets vendors ship unverified.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/veterinary-wolverine-stack-mainstream</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/veterinary-wolverine-stack-mainstream.jpg</image:loc>
      <image:title><![CDATA[Viral 'Wolverine Stack' Videos Push Unapproved Peptides Into Dog Care Without Safety Data]]></image:title>
      <image:caption><![CDATA[An eleven-year-old dog's mobility video went viral in August 2026, accelerating interest in the unapproved BPC-157 and TB-500 combination for pets. Veterinary researchers warn the evidence base consists of rodent studies and a single.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/wada-usada-ncaa-peptide-anti-doping-rules</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/wada-usada-ncaa-peptide-anti-doping-rules.jpg</image:loc>
      <image:title><![CDATA[FDA Warning Letters and WADA S0 Sanctions Converge on Unapproved Peptides]]></image:title>
      <image:caption><![CDATA[The FDA cited Gram Peptides for selling unapproved new drugs in March 2026, reinforcing WADA's Section S0 prohibition on non-approved substances that carries automatic sanctions for athletes regardless of vendor labeling or FDA compounding.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/weight-loss-peptides-clinical-mechanisms</loc>
    <lastmod>2026-08-31T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/weight-loss-peptides-clinical-mechanisms.jpg</image:loc>
      <image:title><![CDATA[Phase 3 Readouts Define Weight Loss Peptide Efficacy and Body Composition Trade-offs]]></image:title>
      <image:caption><![CDATA[Tirzepatide achieved 22.5% mean weight loss in SURMOUNT-1 compared to 14.9% for semaglutide in STEP 1, while DEXA substudies confirm lean mass constitutes 25% to 40% of total reduction across incretin classes.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-telehealth-glp1-marketing-warning-letters</loc>
    <lastmod>2026-08-28T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-telehealth-glp1-marketing-warning-letters.jpg</image:loc>
      <image:title><![CDATA[FDA Slaps 30 Telehealth Firms with Warning Letters Over Compounded GLP-1 Marketing]]></image:title>
      <image:caption><![CDATA[FDA Commissioner Marty Makary called it a new era of enforcement. Thirty telehealth companies received warning letters for marketing compounded GLP-1 drugs as equivalent to Ozempic and Mounjaro, with 15 business days to correct violations.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/samsung-biologics-polypeptide-acquisition-2-2b</loc>
    <lastmod>2026-08-28T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/samsung-biologics-polypeptide-acquisition-2-2b.jpg</image:loc>
      <image:title><![CDATA[Samsung Biologics Approves $2.2B Rights Offering to Fund PolyPeptide Deal]]></image:title>
      <image:caption><![CDATA[Samsung Biologics voted August 28 to raise 3 trillion won through a rights offering, dedicating most proceeds to its record PolyPeptide Group purchase and the rest to a sixth plant in Incheon. Shares fell on dilution concerns.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/samsung-biologics-polypeptide-acquisition-funding</loc>
    <lastmod>2026-08-28T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/samsung-biologics-polypeptide-acquisition-funding.jpg</image:loc>
      <image:title><![CDATA[Samsung Biologics Prices $2.2B Rights Offering to Close PolyPeptide Acquisition]]></image:title>
      <image:caption><![CDATA[The Aug. 28 rights offering prices 2.27 million shares at 1.322 million won each, directing 2.71 trillion won to the Swiss CDMO deal and 294.8 billion won to Bio Campus II expansion.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/glutathione-iv-reactions-supplier-lot</loc>
    <lastmod>2026-08-27T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/glutathione-iv-reactions-supplier-lot.jpg</image:loc>
      <image:title><![CDATA[FDA Trace of 30 IV Glutathione Reactions to Medisca Lot 229536 Exposes Compounding Gap]]></image:title>
      <image:caption><![CDATA[The FDA issued an alert on August 27 linking at least 30 severe patient reactions to Medisca Inc. Lot 229536. The ingredient carried a dietary-supplement label but was compounded into IV drips by multiple pharmacies, bypassing sterility.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/retatrutide-early-access-expansion</loc>
    <lastmod>2026-08-27T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/retatrutide-early-access-expansion.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Expands 'Early Access' to Retatrutide as Black Market Pressure Builds]]></image:title>
      <image:caption><![CDATA[Six weeks after a single 79-year-old patient received compassionate-use retatrutide, Eli Lilly confirmed a formal expanded access pathway on August 3 and filed six lawsuits against black-market sellers nine days later. The dual strategy.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/ai-venom-peptide-antibiotic-discovery</loc>
    <lastmod>2026-08-26T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ai-venom-peptide-antibiotic-discovery.jpg</image:loc>
      <image:title><![CDATA[AI Screened 40 Million Venom Sequences to Find Next-Gen Antibiotics]]></image:title>
      <image:caption><![CDATA[University of Pennsylvania researchers used the APEX model to scan 40.6 million venom-encrypted peptides and identified 386 candidates. Of the 58 peptides synthesized for bench testing, 53 killed drug-resistant bacteria without harming.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/cagrilintide-semaglutide-combo-phase-3-results</loc>
    <lastmod>2026-08-25T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cagrilintide-semaglutide-combo-phase-3-results.jpg</image:loc>
      <image:title><![CDATA[CagriSema Phase 3 Data Show 22.7% Mean Weight Loss, 60% Hit 20% Mark]]></image:title>
      <image:caption><![CDATA[In a 3,417-patient Phase IIIa trial across 22 countries, Novo Nordisk's once-weekly CagriSema combination produced a 22.7% mean weight reduction and placed 60% of participants above the 20% loss threshold, exceeding semaglutide and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/canine-biohacking-pet-peptide-therapy-trend</loc>
    <lastmod>2026-08-25T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/canine-biohacking-pet-peptide-therapy-trend.jpg</image:loc>
      <image:title><![CDATA[Pet Owners Inject Dogs With 'Wolverine Stack' as FDA Panel Vote Fuels Uncertainty]]></image:title>
      <image:caption><![CDATA[The surge in social media posts showing aging dogs regaining mobility after BPC-157 injections has outpaced regulatory safeguards. While an FDA advisory panel recently voted to recommend six peptides for compounding, the agency maintains.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/australia-contaminated-peptide-liver-damage-alert</loc>
    <lastmod>2026-08-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/australia-contaminated-peptide-liver-damage-alert.jpg</image:loc>
      <image:title><![CDATA[Victoria's Seventh Liver Injury Fuels Contaminated-Batch Hypothesis]]></image:title>
      <image:caption><![CDATA[Seven Victorian patients hospitalized with acute liver toxicity after injecting counterfeit retatrutide have prompted doctors and the TGA to publicly raise a contaminated-batch hypothesis, though forensic testing has not yet identified the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/australia-counterfeit-peptide-liver-toxicity-clusters</loc>
    <lastmod>2026-08-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/australia-counterfeit-peptide-liver-toxicity-clusters.jpg</image:loc>
      <image:title><![CDATA[Victorian Doctors Warn of 'Contaminated Batch' Linked to Seven Cases of Liver Failure]]></image:title>
      <image:caption><![CDATA[Liver transplant specialist Marie Sinclair reported a seventh Victorian patient with acute liver toxicity after injecting unapproved retatrutide. The TGA's Robyn Langham called the localized cluster a likely 'batch problem,' while Sinclair.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/counterfeit-peptide-batch-liver-damage-australia</loc>
    <lastmod>2026-08-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/counterfeit-peptide-batch-liver-damage-australia.jpg</image:loc>
      <image:title><![CDATA[Seven Victorians Hospitalized as Doctors Link Counterfeit Peptide Batch to Liver Damage]]></image:title>
      <image:caption><![CDATA[Liver transplant specialists in Melbourne are investigating a cluster of seven hospitalizations linked to counterfeit retatrutide. TGA officials suggest a localized 'batch problem' rather than inherent drug toxicity, highlighting the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/counterfeit-peptide-batch-liver-toxicity-australia</loc>
    <lastmod>2026-08-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/counterfeit-peptide-batch-liver-toxicity-australia.jpg</image:loc>
      <image:title><![CDATA[TGA Flags 'Batch Problem' in Counterfeit Retatrutide Amid Seventh Victorian Liver Injury]]></image:title>
      <image:caption><![CDATA[The Therapeutic Goods Administration has identified a 'localised' cluster of liver injuries in Victoria linked to counterfeit retatrutide. As the seventh patient is hospitalized, officials warn that unapproved products sold online bypass.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-grifters-backlash-rfk-peptide-push</loc>
    <lastmod>2026-08-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-grifters-backlash-rfk-peptide-push.jpg</image:loc>
      <image:title><![CDATA[FDA Panel's 'Grifters' Accusation: The Backlash Against RFK Jr.'s Peptide Push]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, TB-500, and four other peptides for the 503A Bulks List, overriding internal safety concerns. Critics now argue the panel's composition reflects political.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/rfk-jr-fda-panel-grifters-peptide-vote</loc>
    <lastmod>2026-08-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/rfk-jr-fda-panel-grifters-peptide-vote.jpg</image:loc>
      <image:title><![CDATA[The 'Grifter' Panel: RFK Jr.'s FDA Advisers Override Science on BPC-157 and TB-500]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, TB-500, and four other peptides for the 503A Bulks List, overriding career scientists who cited insufficient safety data. A new viewpoint labels the panel.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/victoria-contaminated-peptide-batch-liver-toxicity</loc>
    <lastmod>2026-08-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/victoria-contaminated-peptide-batch-liver-toxicity.jpg</image:loc>
      <image:title><![CDATA[Victoria's Seventh Liver-Toxicity Case Linked to Contaminated Peptide Batch]]></image:title>
      <image:caption><![CDATA[Liver transplant specialist Dr Marie Sinclair confirmed the seventh case of acute liver injury linked to unapproved retatrutide in Victoria, raising the possibility that a contaminated counterfeit batch is circulating. The TGA calls it a.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/cagrilintide-semaglutide-combo-trial-results</loc>
    <lastmod>2026-08-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cagrilintide-semaglutide-combo-trial-results.jpg</image:loc>
      <image:title><![CDATA[REDEFINE 1: Cagrilintide–Semaglutide Combo Delivers 20%+ Weight Loss in 60% of Patients]]></image:title>
      <image:caption><![CDATA[In the REDEFINE 1 trial, Novo Nordisk's dual-mechanism injectable CagriSema delivered mean weight loss of 20.4% at 68 weeks, and 60% of adherent participants shed at least a fifth of their body weight, outpacing semaglutide or cagrilintide.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/cagrilintide-semaglutide-combo-trial-results-weight-loss</loc>
    <lastmod>2026-08-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cagrilintide-semaglutide-combo-trial-results-weight-loss.jpg</image:loc>
      <image:title><![CDATA[Cagrilintide-Semaglutide Combo Achieves 20%+ Weight Loss in REDEFINE 1 Trial]]></image:title>
      <image:caption><![CDATA[Sixty percent of REDEFINE 1 participants achieved 20% or greater body-weight reduction on the cagrilintide-semaglutide combination, a threshold previously linked to bariatric surgery. The drug has no FDA approval, no published price, and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/glutathione-recall-bacterial-toxin-2026</loc>
    <lastmod>2026-08-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/glutathione-recall-bacterial-toxin-2026.jpg</image:loc>
      <image:title><![CDATA[Second Texas Pharmacy Recalls Glutathione Amid 'Deadly' Bacterial Toxin Alarms]]></image:title>
      <image:caption><![CDATA[Houston-based Optimal Balance Pharmacy recalled lot LG342009076 of compounded glutathione on August 19, 2026, after pharmacy testing found elevated bacterial endotoxin levels. The FDA published the notice August 20. Two weeks earlier.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-30-warning-letters-telehealth-peptides</loc>
    <lastmod>2026-08-22T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-30-warning-letters-telehealth-peptides.jpg</image:loc>
      <image:title><![CDATA[FDA's 30 Warning Letters: The 'Telehealth Peptide' Crackdown Begins in Earnest]]></image:title>
      <image:caption><![CDATA[Thirty telehealth firms received FDA warning letters for implying compounded GLP-1 products were interchangeable with Wegovy and Zepbound. The letters carry a 15-day compliance deadline and threats of seizure.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/pet-peptide-boom-bpc-157-dog-owners</loc>
    <lastmod>2026-08-22T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/pet-peptide-boom-bpc-157-dog-owners.jpg</image:loc>
      <image:title><![CDATA[Dog Owners Inject BPC-157 and TB-500 as FDA Compounding Vote Fuels a Pet Peptide Surge]]></image:title>
      <image:caption><![CDATA[After the FDA advisory panel's July 2026 vote on compounding access, dog owners are administering BPC-157 and TB-500 using dosing figures drawn from informal sources. No canine clinical trial supports the practice, and no veterinary.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/veterinary-wolverine-stack-trend</loc>
    <lastmod>2026-08-22T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/veterinary-wolverine-stack-trend.jpg</image:loc>
      <image:title><![CDATA[Viral Dog-Peptide Videos Outpace Veterinary Safety Data After FDA Vote]]></image:title>
      <image:caption><![CDATA[Pet owners are injecting aging dogs with BPC-157 after viral mobility videos, while veterinary clinicians warn no published trial establishes a safe canine dose. The FDA's July advisory vote addressed human compounding only.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/amino-acid-chart</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/amino-acid-chart.jpg</image:loc>
      <image:title><![CDATA[The 20 Standard Amino Acids: Verified Codes, Weights, and pKa Values for Peptide Work]]></image:title>
      <image:caption><![CDATA[Peptide chemists rely on precise nomenclature to avoid synthesis errors. This reference details the trivial and systematic names, one- and three-letter codes, and key physicochemical properties of the 20 standard amino acids.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/are-peptides-banned-by-ncaa</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/are-peptides-banned-by-ncaa.jpg</image:loc>
      <image:title><![CDATA[Are Peptides Banned by the NCAA? Rules and Verification]]></image:title>
      <image:caption><![CDATA[The NCAA explicitly bans peptide hormones, growth factors, and related substances. This prohibition applies year-round. A positive test for BPC-157 or MK-677 results in a minimum one-year loss of eligibility, with very narrow exceptions.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/are-peptides-legal</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/are-peptides-legal.jpg</image:loc>
      <image:title><![CDATA[Are Peptides Legal? FDA Tiers, Compounding Bans, and the 2026 Regulatory Gap]]></image:title>
      <image:caption><![CDATA[Not all peptides are legal in the United States. FDA-approved drugs like insulin are lawful, while unapproved compounds face strict compounding bans. Recent regulatory shifts have created a complex landscape where legality hinges on.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/are-research-peptides-safe</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/are-research-peptides-safe.jpg</image:loc>
      <image:title><![CDATA[FDA Vote Puts Unapproved Peptides in Compounding Pharmacies Despite Safety Warnings]]></image:title>
      <image:caption><![CDATA[FDA advisers voted to allow compounding pharmacies to produce six unapproved peptides. The decision overrides agency warnings that these products lack human trial data and carry risks of contamination and incorrect dosing.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/building-blocks-of-proteins</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/building-blocks-of-proteins.jpg</image:loc>
      <image:title><![CDATA[Protein Sequence as Regulatory Proof: Why Amino Acid Identity Drives Compliance]]></image:title>
      <image:caption><![CDATA[The specific arrangement of 20 amino acids determines protein folding and function. Regulatory agencies treat this sequence as a critical quality attribute for approval.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/custom-peptide-synthesis</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/custom-peptide-synthesis.jpg</image:loc>
      <image:title><![CDATA[Custom Peptide Synthesis: Process and Quality Controls]]></image:title>
      <image:caption><![CDATA[Custom peptide synthesis uses solid-phase synthesis to construct user-defined sequences. Chemists verify each step via in-process testing, while post-synthesis quality control uses mass spectrometry and HPLC to confirm purity tiers.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/fda-approved-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-approved-peptides.jpg</image:loc>
      <image:title><![CDATA[FDA-Approved Peptides: What Approval Actually Means]]></image:title>
      <image:caption><![CDATA[While semaglutide and insulin are approved drugs with validated safety data, peptides like BPC-157 and TB-500 are not. Understanding the difference between drug approval and compounding eligibility is critical for patient safety.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/ghrp-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ghrp-peptides.jpg</image:loc>
      <image:title><![CDATA[GHRP Peptides: Potent Growth Hormone Triggers Lack FDA Approval and Remain Banned in Sport]]></image:title>
      <image:caption><![CDATA[GHRP-2 and GHRP-6 are synthetic peptides that trigger growth hormone release by acting on the ghrelin receptor. Despite documented physiological activity, neither holds FDA approval, and both are prohibited by WADA under Category S2.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/grey-market-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/grey-market-peptides.jpg</image:loc>
      <image:title><![CDATA["Research Use Only" Labels Cannot Substitute for GMP Standards in the Peptide Market]]></image:title>
      <image:caption><![CDATA["Legal to sell and entirely unpoliced for quality," grey market peptides operate in a regulatory vacuum where "research use only" labels do not guarantee purity, sterility, or accurate dosing. Independent lab analyses have found endotoxin.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/high-purity-research-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/high-purity-research-peptides.jpg</image:loc>
      <image:title><![CDATA[Decoding Purity Claims in Research Peptide COAs]]></image:title>
      <image:caption><![CDATA[A purity percentage on a label is not evidence; it is a claim. High-purity research peptides require verification via third-party Certificates of Analysis (COAs) that detail HPLC and mass spectrometry results. This reference explains how.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/oral-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oral-peptides.jpg</image:loc>
      <image:title><![CDATA[Why Oral Peptides Are Hard to Deliver]]></image:title>
      <image:caption><![CDATA[Pepsin and other enzymes dismantle peptides in the stomach within minutes. While oral semaglutide succeeds due to a specific permeation enhancer, standard capsules deliver negligible systemic exposure. This is the core challenge for any.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-bond</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-bond.jpg</image:loc>
      <image:title><![CDATA[How Peptide Bonds Form: The Chemistry Behind the Peptide Backbone]]></image:title>
      <image:caption><![CDATA[A peptide bond is a specific amide linkage connecting the carboxyl group of one amino acid to the amino group of the next. Understanding this covalent bond is essential for grasping peptide structure, from simple dipeptides to complex.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-structure</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-structure.jpg</image:loc>
      <image:title><![CDATA[Reading the Peptide Blueprint: How Sequence Dictates 3D Function]]></image:title>
      <image:caption><![CDATA[The linear sequence of amino acids is the primary structure of a peptide, serving as the blueprint for its higher-order folding. Understanding how secondary structures like alpha-helices form, and how tertiary interactions stabilize the 3D.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptide-testing</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptide-testing.jpg</image:loc>
      <image:title><![CDATA[Peptide Testing: Identity, Purity, and Analytical Limits]]></image:title>
      <image:caption><![CDATA[Peptide testing is not a single assay but a multi-modal verification process. This guide distinguishes between identity confirmation, chromatographic purity, and quantitative content, detailing how mass spectrometry and HPLC function.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/peptides-for-healing</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/peptides-for-healing.jpg</image:loc>
      <image:title><![CDATA[The Evidence Gap: What We Actually Know About Peptides for Healing]]></image:title>
      <image:caption><![CDATA[In gym culture, peptides are often presented as a next-step recovery tool. Yet the human evidence base is thin. Most claims rely on animal studies, while clinical data remains limited, small-scale, and poorly controlled.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/research-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/research-peptides.jpg</image:loc>
      <image:title><![CDATA[Research Peptides: Regulatory Status, Analytical Verification, and Lab Integrity]]></image:title>
      <image:caption><![CDATA[Research peptides sold for laboratory use have not been evaluated or approved by the FDA. Their scientific validity relies entirely on analytical purity and identity verification. A 2020 peer-reviewed review establishes that peptides.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/weight-loss-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/weight-loss-peptides.jpg</image:loc>
      <image:title><![CDATA[Weight Loss Peptides: FDA Approval vs. Experimental Status]]></image:title>
      <image:caption><![CDATA[Only three injectable peptide therapies are currently FDA-approved for chronic weight management. This guide distinguishes regulatory status, clinical trial data, and safety profiles for approved therapies versus unregulated research.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/what-are-amino-acids</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/what-are-amino-acids.jpg</image:loc>
      <image:title><![CDATA[The 20-Residue Alphabet: A Precise Definition of Amino Acids]]></image:title>
      <image:caption><![CDATA[Amino acids are organic molecules containing both amino and carboxylic acid groups. While over 500 exist in nature, only 20 are incorporated into proteins by the genetic code. This article defines the alpha-carbon structure, classifies.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/what-are-peptides</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/what-are-peptides.jpg</image:loc>
      <image:title><![CDATA[What Are Peptides? Structure, Types, and Uses]]></image:title>
      <image:caption><![CDATA[Peptides occupy a pharmacological niche between small-molecule drugs and large proteins, defined by chains of two to 50 amino acids linked by peptide bonds. This explainer clarifies the chemistry, regulatory status, and clinical.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/guides/wolverine-stack-peptide</loc>
    <lastmod>2026-08-21T18:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.8</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/wolverine-stack-peptide.jpg</image:loc>
      <image:title><![CDATA[Wolverine Stack Surge: Clinics Push BPC-157 and TB-500 Blend Amid Regulatory Gaps]]></image:title>
      <image:caption><![CDATA[The 'Wolverine Stack' has moved from online forums to physical exam rooms, with providers in Florida, Texas, and Connecticut marketing a combined BPC-157 and TB-500 protocol. While preclinical data supports individual tissue repair.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/rogan-damon-wolverine-stack-doping-ban</loc>
    <lastmod>2026-08-20T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/rogan-damon-wolverine-stack-doping-ban.jpg</image:loc>
      <image:title><![CDATA[USADA Bans Weightlifter as 'Wolverine Stack' Celebrity Hype Collides with Doping Rules]]></image:title>
      <image:caption><![CDATA[Weightlifter Jara MacDermott accepted a two-year ineligibility on August 20, 2026, for testing positive for canrenone, amphetamine, and testosterone. The sanction landed eight days after USADA publicly flagged BPC-157 as a banned peptide.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/usada-suspends-weightlifter-peptide-use</loc>
    <lastmod>2026-08-20T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/usada-suspends-weightlifter-peptide-use.jpg</image:loc>
      <image:title><![CDATA[USADA Suspends Weightlifter for Peptide Use, Igniting 'Peptide Ban' Debate in Elite Sports]]></image:title>
      <image:caption><![CDATA[Weightlifter Jara MacDermott accepted a two-year period of ineligibility on August 20, 2026, for testing positive for canrenone, amphetamine, and testosterone. The announcement arrives eight days after USADA publicly flagged BPC-157 as a.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/oral-wegovy-launch-impact-peptide-market</loc>
    <lastmod>2026-08-19T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oral-wegovy-launch-impact-peptide-market.jpg</image:loc>
      <image:title><![CDATA[Oral Wegovy's Launch Reshapes the Peptide Hierarchy: Injection vs. Pill]]></image:title>
      <image:caption><![CDATA[The FDA cleared oral semaglutide 25 mg as the first GLP-1 pill for weight loss on December 22, 2025. Truveta data shows the pill drew thousands of new patients into GLP-1 therapy. Eli Lilly's orforglipron awaits FDA review.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/kailera-therapeutics-obesity-ipo-analysis</loc>
    <lastmod>2026-08-18T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/kailera-therapeutics-obesity-ipo-analysis.jpg</image:loc>
      <image:title><![CDATA[Kailera's $625M IPO Leaves Big Pharma Deciding Between Licensing Ribupatide or Competing]]></image:title>
      <image:caption><![CDATA[Kailera Therapeutics closed at $18.51 on August 18, down 28.8% from its record-breaking April IPO. The Waltham biotech, spun out of Hengrui Pharma, holds $1.17 billion in cash and a dual GIP/GLP-1 agonist in global Phase 3.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/unregulated-mots-c-use-researchers-warn</loc>
    <lastmod>2026-08-18T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/unregulated-mots-c-use-researchers-warn.jpg</image:loc>
      <image:title><![CDATA[Researchers Warn of Unregulated MOTS-c Sales in 'Gym Rat' Community]]></image:title>
      <image:caption><![CDATA[The USC gerontologist who identified MOTS-c is sounding the alarm on a thriving online trade that sells the mouse-exercise peptide to consumers without purity or sterility guarantees.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/verlytix-peptide-testing-expansion</loc>
    <lastmod>2026-08-18T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/verlytix-peptide-testing-expansion.jpg</image:loc>
      <image:title><![CDATA[Verlytix Launches Peptide QC Platform Tied to LyoGenesis Manufacturing]]></image:title>
      <image:caption><![CDATA[The Mequon, Wis., contract lab announced an expanded quality analytical testing platform for peptides, with Vector Science & Therapeutics as its first named client under a LyoGenesis Holdings agreement.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/longevity-peptides-science-reality-check</loc>
    <lastmod>2026-08-17T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/longevity-peptides-science-reality-check.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Vote Opens Compounding Path for Epitalon and MOTS-c, but Human Trials Are Sti]]></image:title>
      <image:caption><![CDATA[The FDA advisory panel voted to recommend compounding access for two longevity peptides, Epitalon and MOTS-c, while its own staff argued the evidence was insufficient. New expert reviews lay out how far the science remains from the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/rfk-jr-peptide-politics-fda-science</loc>
    <lastmod>2026-08-17T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/rfk-jr-peptide-politics-fda-science.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Panel Sides With Kennedy's Peptide Agenda Over Its Own Scientists' Warnings]]></image:title>
      <image:caption><![CDATA[A narrowly composed FDA advisory panel recommended placing six unproven peptides into a category that permits pharmacy compounding, over the objections of career scientists. The vote follows HHS Secretary RFK Jr.'s personal advocacy and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/aizen-ai-peptide-collaboration-100m</loc>
    <lastmod>2026-08-16T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/aizen-ai-peptide-collaboration-100m.jpg</image:loc>
      <image:title><![CDATA[Aizen Signs $100M AI Peptide Deal]]></image:title>
      <image:caption><![CDATA[Aizen Therapeutics, a San Diego-based AI biotech spun out of Caltech, has entered a multi-program collaboration with an undisclosed public partner. The deal includes upfront funding and up to $100 million in milestone payments per target.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-votes-six-peptides-category-1-compounding</loc>
    <lastmod>2026-08-15T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-votes-six-peptides-category-1-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Staff Opposed All Seven Peptides. The Advisory Panel Overruled Them.]]></image:title>
      <image:caption><![CDATA[FDA staff scientists recommended against every peptide under review. The advisory panel voted six through anyway, citing grey-market harm. Formal rulemaking now determines whether compounding pharmacies gain legal access.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-lawsuits-illicit-peptide-market</loc>
    <lastmod>2026-08-12T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-lawsuits-illicit-peptide-market.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Targets Illicit Market for Unapproved Weight-Loss Peptide]]></image:title>
      <image:caption><![CDATA[The drugmaker is suing four online peptide sellers, a California med spa, and a compounding pharmacy for marketing an unapproved triple-receptor agonist to consumers under a 'research use' label.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-retatrutide-black-market-lawsuits</loc>
    <lastmod>2026-08-12T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-retatrutide-black-market-lawsuits.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Files Six Federal Lawsuits to Dismantle the Retatrutide 'Research-Use Only' Mark]]></image:title>
      <image:caption><![CDATA[Eli Lilly filed six federal lawsuits against compounding pharmacies, med spas, and online sellers marketing unapproved retatrutide as 'research-use only,' challenging a labeling convention the drugmaker says conceals illegal human.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-retatrutide-lawsuit-enforcement</loc>
    <lastmod>2026-08-12T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-retatrutide-lawsuit-enforcement.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Sues Six Retatrutide Sellers, Escalating Beyond Agency Referrals]]></image:title>
      <image:caption><![CDATA[On August 12, 2026, Eli Lilly sued Aesthetic Envy, Astra, and four other entities over alleged illegal sales of its investigational obesity drug retatrutide. The company has referred over 200 entities to regulators and flagged 14,000.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-sues-retatrutide-black-market-sellers</loc>
    <lastmod>2026-08-12T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-sues-retatrutide-black-market-sellers.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Sues Six Sellers Over Unapproved Retatrutide Sales]]></image:title>
      <image:caption><![CDATA[Eli Lilly filed six federal lawsuits on August 12, 2026, against Aesthetic Envy, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. The complaints allege these businesses sold illegal versions of.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-vote-implications-grey-market-peptides</loc>
    <lastmod>2026-08-11T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-vote-implications-grey-market-peptides.jpg</image:loc>
      <image:title><![CDATA[FDA Panel's Narrow Vote Leaves BPC-157 and Semax in Regulatory Limbo]]></image:title>
      <image:caption><![CDATA[The PCAC's July 23–24 votes to recommend BPC-157, Semax, and four other peptides for compounding eligibility override FDA scientists' unanimous opposition. Legal access still requires a rulemaking process with no set timeline.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/aleniglipron-oral-glp1-12-weight-loss</loc>
    <lastmod>2026-08-10T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/aleniglipron-oral-glp1-12-weight-loss.jpg</image:loc>
      <image:title><![CDATA[Aleniglipron Posts 12.1% Weight Loss in Phase 2b Trial, Testing the GLP-1 Access Gap]]></image:title>
      <image:caption><![CDATA[A once-daily tablet from Structure Therapeutics achieved weight loss comparable to injectable semaglutide in a randomized trial, but the 230-person, U.S.-only Phase 2b design leaves open whether the access benefits of a small-molecule.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/stanford-experts-peptide-evidence-reality-check</loc>
    <lastmod>2026-08-10T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/stanford-experts-peptide-evidence-reality-check.jpg</image:loc>
      <image:title><![CDATA[Stanford Pathologists Say Popular Peptide Injections Lack a Single Controlled Human Trial]]></image:title>
      <image:caption><![CDATA[Two Stanford pathologists published an evidence review on August 12 separating FDA-approved peptide drugs from the unapproved compounds trending on social media, warning that most popular injectables have never entered a controlled human.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/canine-biohacking-peptide-mobility-recovery</loc>
    <lastmod>2026-08-08T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/canine-biohacking-peptide-mobility-recovery.jpg</image:loc>
      <image:title><![CDATA[Viral 'Wolverine' Peptide Videos for Dogs Draw Veterinary Warnings Amid Regulatory Vacuum]]></image:title>
      <image:caption><![CDATA[An 11-year-old dog's mobility transformation in a viral video has pet owners reaching for the same BPC-157 and TB-500 combination that biohackers call the Wolverine Stack. Veterinary professionals say no peer-reviewed trial supports the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/celebrity-influencer-peptide-boom</loc>
    <lastmod>2026-08-08T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/celebrity-influencer-peptide-boom.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Endorses Peptides Promoted by Rogan and RFK Jr., Bending Regulation Toward Podca]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23 to recommend placing BPC-157, TB-500, and other peptides on the agency's bulks list, a shift that follows years of promotion by Joe Rogan, RFK Jr., and wellness clinic.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/dog-peptide-therapy-bpc-157-trend</loc>
    <lastmod>2026-08-08T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/dog-peptide-therapy-bpc-157-trend.jpg</image:loc>
      <image:title><![CDATA[Canine Biohacking: Inside the 'Wolverine Stack' Trend for Aging Dogs]]></image:title>
      <image:caption><![CDATA[The July 23 PCAC vote recommended six peptides for human compounding despite career scientists citing absent safety data. The decision amplified demand across informal markets, including pet-care channels where no dosing evidence exists.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/wolverine-stack-science-analysis</loc>
    <lastmod>2026-08-06T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/wolverine-stack-science-analysis.jpg</image:loc>
      <image:title><![CDATA[The 'Wolverine Stack' Boom: What the Science Says About BPC-157 and TB-500]]></image:title>
      <image:caption><![CDATA[Social media celebrates the Wolverine Stack as a shortcut to rapid injury healing. Stanford Medicine and AMA experts counter that no controlled human trial has tested BPC-157 and TB-500 together, and the FDA's Category 2 designation bars.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/australia-tga-peptide-crackdown</loc>
    <lastmod>2026-08-02T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/australia-tga-peptide-crackdown.jpg</image:loc>
      <image:title><![CDATA[Australia's TGA Cracks Down on Influencer-Driven Peptide Sales After Finding Deadly Contam]]></image:title>
      <image:caption><![CDATA[Forensic analysis of peptides sold through Facebook Marketplace and Australia Post revealed empty vials, wildly inconsistent dosing, and trace heavy metals. Australia's TGA responded by elevating unapproved peptides to a priority.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/ultrarunner-bpc-157-doping-ban</loc>
    <lastmod>2026-07-24T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ultrarunner-bpc-157-doping-ban.jpg</image:loc>
      <image:title><![CDATA[Ultrarunner Mike McKnight's BPC-157 Admission Forces Anti-Doping Reckoning in Endurance Ra]]></image:title>
      <image:caption><![CDATA[Mike McKnight told Cam Hanes' podcast audience that BPC-157 healed his herniated disc and let him cancel surgery. USADA prohibits the peptide at all times. The FDA just voted to let compounding pharmacies make it.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-backs-peptides-compounding-what-it-means</loc>
    <lastmod>2026-07-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-backs-peptides-compounding-what-it-means.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Backs Six Peptides for Compounding Over Agency Objections]]></image:title>
      <image:caption><![CDATA[On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee narrowly recommended six wellness peptides for the Section 503A Bulks List, overriding career scientists who advised against all seven compounds under review. Final.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-votes-loosen-peptide-restrictions</loc>
    <lastmod>2026-07-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-votes-loosen-peptide-restrictions.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Backs Compounding of Four Unapproved Peptides]]></image:title>
      <image:caption><![CDATA[An FDA advisory panel narrowly recommended reclassifying four unapproved peptides from a prohibited-compounding category to one that permits licensed pharmacies to prepare them. The vote does not constitute drug approval, and formal.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-peptide-compounding-panel-vote-safety-overruled</loc>
    <lastmod>2026-07-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-peptide-compounding-panel-vote-safety-overruled.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Backs 6 Peptides for Compounding, Overruling Agency Scientists' Safety Warnings]]></image:title>
      <image:caption><![CDATA[FDA career scientists recommended against all seven peptides under review. The advisory committee voted to advance six of them anyway, by margins as thin as 7-5, in a meeting shaped by eight members appointed weeks earlier.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-peptide-vote-consumer-safety-crisis</loc>
    <lastmod>2026-07-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-peptide-vote-consumer-safety-crisis.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Panel Overrides Agency Scientists to Recommend Six Peptides for Compounding]]></image:title>
      <image:caption><![CDATA[Fourteen outside advisers split 8-6 to recommend six injectable peptides for compounding pharmacy access, rejecting FDA staff warnings that none has passed rigorous human trials. The non-binding vote aligns with Health Secretary RFK Jr.'s.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-peptide-vote-patent-consumer-impact</loc>
    <lastmod>2026-07-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-peptide-vote-patent-consumer-impact.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Votes to Compound Six Peptides, Overriding Safety Warnings]]></image:title>
      <image:caption><![CDATA[The FDA's advisory committee voted narrowly to recommend six popular peptides for compounding, overruling agency scientists who cited a lack of human safety data. The vote is a nonbinding recommendation that must survive formal rulemaking.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/rfk-jr-fda-peptide-vote-analysis</loc>
    <lastmod>2026-07-23T18:00:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/rfk-jr-fda-peptide-vote-analysis.jpg</image:loc>
      <image:title><![CDATA[Inside the FDA Vote: How the 'RFK Jr. Effect' Reshaped Peptide Policy]]></image:title>
      <image:caption><![CDATA[On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding six peptides to the 503A compounding list, directly contradicting the agency's own scientific staff. The vote is.]]></image:caption>
    </image:image>
  </url>
</urlset>